Large cardiovascular outcome trials and meta-analyses have shown that GLP-1 RAs significantly reduce MACE, cardiovascular mortality, stroke, and all-cause mortality across a wide range of patients with and without prior CVD (65, 68, 69). Here, GLP1R is linked to Stroke.